Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II oxaliplatin + capecitabine in advanced oesophageal cancer
ISRCTN07447845Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Apr 2003
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and capecitabine in esophageal cancer and esophagogastric junction cancer, sponsored by Erasmus MC. Primary endpoints: Response rate, Time to progression and 2 more. Started Apr 2003; status: completed.
02
Drugs
oxaliplatincapecitabine
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on ISRCTN07447845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN07447845.